diet a risk factor for benign prostatic hyperplasia and carcinoma prostate?

To find an association between diet and benign prostatic hyperplasia [BPH] and carcinoma prostate [CaP]. Ninety three out of 250 subjects were selected representing the normals, BPH and CaP cases; food frequency questionnaire was duly filled. Food intake was calculated by using food guide pyramid and was categorized as low, moderate and high. In addition to common diets, we studied consumption of reused oil/ghee in our study. No association of protein, milk and milk products, cereals, fats [saturated/ unsaturated/both fats, oil/ghee branded or unbranded], vegetables, fruits and smoked food/barbecue was found with BPH and CaP cases. But there was a significant association between oil/ghee reuse and BPH and CaP. This study did not find an association between the common diet components and BPH and CaP cases. However a significant association was observed in case of oil/ghee reuse. So it is concluded that commonly used diet components in our setup could not be incriminated as etiological/risk factors for BPH and CaP in our community except reused oil/ghee and hence forth its consumption must be stopped

Prostate cancer and acromegaly: [review] / Câncer de próstata e acromegalia: [revisão]

Acromegalic patients have an increased prevalence of prostatic disorders compared to age-matched healthy subjects. Increased size of the whole prostate or the transitional zone, together with an elevated incidence of other structural changes, such as nodules, cysts, and calcifications, have been reported. Prostate enlargement in young acromegalic patients with low testosterone levels due to central hypogonadism supports the hypothesis that chronic GH and IGF-I excess cause prostate hyperplasia. The relationship between prostatic carcinoma and acromegaly is, until now, only circumstantial. Long-term follow-up of these patients is necessary since epidemiologic studies showed association between serum IGF-I levels in the upper normal limit and prostate cancer in the general population. This review approaches prostate diseases in patients with acromegaly.

Pacientes com acromegalia têm uma prevalência aumentada de desordens prostáticas em comparação a controles saudáveis da mesma idade. Aumento do tamanho de toda a próstata ou da zona de transição, juntamente com uma incidência elevada de outras alterações estruturais, como nódulos, cistos e calcificações, foi descrito. O aumento da próstata em acromegálicos jovens e com níveis baixos de testosterona devido ao hipogonadismo central sugere que o excesso crônico do GH e do IGF-I cause hiperplasia prostática. A relação entre câncer de próstata e acromegalia é, até o momento, apenas circunstancial. Entretanto, um seguimento prolongado desses pacientes é necessário uma vez que estudos epidemiológicos reportaram uma associação entre níveis séricos de IGF-I no limite superior da normalidade e câncer de próstata na população geral. Esta revisão aborda as patologias prostáticas em pacientes com acromegalia.

"Uso de sonda foley de tres vías" en adenomectomía prostática suprapubica en el hosptial Escuela Dr. Roberto Calderón Gutiérrez enero 1994 a abril 1999

Se presenta un trabajo de tipo descriptivo siendo una serie de casos de los pacientes intervenidos quirúrgicamente por Hipertrofia Prostática en el período de Enero de 1994 a Abril de 1999 usando sonda foley de 3 vías. Dichos pacientes se les realizó adenomectomía suprapúbica, siendo manejado con sonda foley No. 24 de 3 vías con balón de 30 cc, dejando el balón en el lecho prostático sin colocación de sonda suprapúbica (talla vesical), y con irrigación continua de la vejiga con solución salina. Los pacientes tenían las caracaterísticas de ser mayores de 40 años y que presentaban sintomatología clínica de Hipertrofia Prostática. Dichos pacientes presentaron una estancia hospitalaria promedio de 6 días con duración del procedimiento quirúrgico de 2 horas y 25 minutos. Siendo más frecuentes le Hipertrofia Prostática III. No se presentaron complicaciones post operatorias y tuvieron buena evolución clínica, valorado por el seguimento en la consulta externa. El estudio nos revela que el manejo pos operatoriocon sonda de 3 vías en los pacientes con hipertrofia prostática es un procedimiento seguro...

La hiperplasia benigna de próstata como consecuencia de un defecto de la UDP-glucuroniltransferasa / Benign prostatic hiperplasia as a consequence of a defective UDP-glucuroniltransferase

La hiperplasia benigna de próstata (HBP), es un hallazgo casi universal en el hombre de edad avanzada. Se requiere la integridad funcional de los testículos para el desarrollo funcional de la HBP. La hipótesis más común para explicar la etiología de la HBP, es la acumulación de la 5Ó-dihidrotestosterona (DHT) en la glándula prostática, posiblemente debido a un aumento de la actividad de la 5Ó-reductasa (5Ó-R). Sin embargo, los niveles plasmáticos y la excreción urinaria del androstano-3Ó, 17ß-diol glucurónido (3Ó-Adiol G) disminuye significativamente, a medida que avanza la edad en el hombre, caracterizando a los pacientes con HBP. Como consecuencia, la tasa de degradación de la DHT se encontraró reducida en el hombre de edad avanzada. Además, el significativo aumento de la concentración del estradiol (E2) en el estroma prostático durante el proceso de envejecimiento, puede ser el responsable de la acumulación de los receptores para estrógenos y andrógenos. Se concluye que el defecto, progresivamente adquirido de la actividad de la UDP-glucuroniltransferasas (UDP-GT) puede disminuir la remoción del 3Ó-Adiol G del tejido prostático, aumentando simultáneamente la acumulación de la DHT

Transvesical prostatectomy for benign prostatic hyperplasia, an experience of 200 cases at Hyderabad

An analysis of 200 patients with benign prostatic hyperplasia who underwent transvesical prostatectomy from January, 1988, to December, 1991, in Surgical Unit II at Liaquat Medical College Hospital Hyderabad, Jamshoro is presented. The age range was 50-90 years, the most frequent group was between 50-60 years. A total of 120 [60%] patients presented with acute retention of urine. All underwent one stage transvesical prostatectomy and almost all were operated under spinal anaesthesia. Vasectomy was not done in any case

Hiperplasia benigna da próstata: tratamento näo cirúrgico / Prostatic hypertrophy: non surgical treatment

Säo apresentadas e discutidas as alternativas näo cirúrgicas ao clássico e eficaz tratamento cirúrgico da Hiperplasia Benigna da Próstata, concluindo-se serem amplamente promissores os métodos alternativos de tratamento em estudo

Hipertrofia benigna da próstata / Benign prostatic hyperplasia

The prostatic hyperplasia takes place in the average and old age male population. It occurs in 23 to 88% of the men between 45 and 90 years old and it may cause severe urinary obstructive symptoms in 10 to 25% of them. A significative amount of that percentage of symptomatic patients deserve treatment. The pharmacologic treatment can bring relief of symptoms for a shorter of longer period of time but it is not the definite solution. In our days the hormones (with anti-androgens effects) and the alfa-1-blockers are used with this purpose. The indications of surgical treatment of benign prostatic hyperplasia are: urinary infection non responsive to medical treatment; uper urinary tract dilatation or acute urinary retention; decrease of the kidney function; behavioral troubles caused by urinary symptoms. The surgical treatment of benign prostatic hyperplasia can be performed by open or trans-urethral surgery. In the urologic centers 90% of prostatic sugeries are trans-urethral resections (T.U.R.) with similar benfits of the open surgery. The T.U.R. is more comfortable and less painful for the patient. Although, the prostatic surgery may cause retrograde ejaculation it does not interfere on the male sexual behavior and capacity